down arrow

Savara, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8051111016
USD
6.40
-0.07 (-1.08%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.336.61

52 Week

1.897.00
Valuation
Technical
Day's Volume

CASH

662.78 k

Shareholding (Mar 2025)

FII

6.73%

Held by 74 FIIs

DII

26.78%

Held by 36 DIIs

Promoter

49.06%

How big is Savara, Inc.?

22-Jun-2025

As of Jun 18, Savara, Inc. has a market capitalization of 352.59 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -102.17 million over the latest four quarters. As of Dec'24, the company reported shareholder's funds of 171.45 million and total assets of 212.88 million.

Market Cap: As of Jun 18, Savara, Inc. has a market capitalization of 352.59 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Savara, Inc. reported net sales of 0.00 million and a net profit of -102.17 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 171.45 million and total assets of 212.88 million.

Read More

What does Savara, Inc. do?

22-Jun-2025

Savara, Inc. is a pharmaceutical company focused on developing and commercializing treatments for orphan lung diseases. As of March 2025, it has a market cap of $352.59 million and reported a net profit loss of $27 million.

Overview: <BR>Savara, Inc. is an orphan lung disease company engaged in the development and commercialization of novel therapeutics in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Profit: -27 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 352.59 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.97 <BR>Return on Equity: -68.74% <BR>Price to Book: 2.38<BR><BR>Contact Details: <BR>Address: 900 S Capital of Texas Hwy Ste 150, WEST LAKE HILLS TX: 78746-5436 <BR>Tel: 1 512 6141848 <BR>Website: http://savarapharma.com/

Read More

Who are in the management team of Savara, Inc.?

22-Jun-2025

As of March 2022, the management team of Savara, Inc. includes Mr. Matthew Pauls as Chairman and CEO, along with independent directors Mr. Nevan Elam, Mr. Richard Hawkins, Dr. Joseph McCracken, Mr. David Ramsay, and Mr. Ricky Sun.

As of March 2022, the management team of Savara, Inc. includes Mr. Matthew Pauls, who serves as the Chairman of the Board and Chief Executive Officer. The Board of Directors also consists of several independent directors: Mr. Nevan Elam, Mr. Richard Hawkins, Dr. Joseph McCracken, Mr. David Ramsay, and Mr. Ricky Sun.

Read More

Is Savara, Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, Savara, Inc. shows a mildly bullish trend with positive short-term indicators, despite mixed signals from longer-term metrics and underperformance over the past year compared to the S&P 500.

As of 19 September 2025, the technical trend for Savara, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is bearish, indicating mixed signals. The RSI is bearish on the weekly timeframe, but there is no signal on the monthly. Bollinger Bands show a mildly bullish stance weekly and mildly bearish monthly. Daily moving averages are bullish, supporting a positive short-term outlook. KST is bullish weekly but bearish monthly, and Dow Theory indicates no trend weekly and mildly bullish monthly. <BR><BR>In terms of performance, Savara has outperformed the S&P 500 over the past month (10.44% vs. 3.95%) and year-to-date (13.68% vs. 13.31%), but it has underperformed over the past year (-22.27% vs. 16.64%). Overall, the current technical stance is mildly bullish, with key indicators such as the daily moving averages and weekly MACD contributing positively, despite mixed signals from other indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 665 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.97

stock-summary
Return on Equity

-91.12%

stock-summary
Price to Book

5.52

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-30 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
83.91%
0%
83.91%
6 Months
196.3%
0%
196.3%
1 Year
96.92%
0%
96.92%
2 Years
30.61%
0%
30.61%
3 Years
326.67%
0%
326.67%
4 Years
396.12%
0%
396.12%
5 Years
370.59%
0%
370.59%

Savara, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-180.93%
EBIT to Interest (avg)
-58.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.97
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.85
EV to EBIT
-2.55
EV to EBITDA
-2.56
EV to Capital Employed
55.83
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2185.31%
ROE (Latest)
-68.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 38 Schemes (17.43%)

Foreign Institutions

Held by 74 Foreign Institutions (6.73%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -36.94% vs -94.74% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.40",
          "val2": "-23.10",
          "chgp": "-35.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.40",
          "val2": "-22.20",
          "chgp": "-36.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.32% vs -43.57% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-102.90",
          "val2": "-59.80",
          "chgp": "-72.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-95.90",
          "val2": "-54.70",
          "chgp": "-75.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-31.40
-23.10
-35.93%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-30.40
-22.20
-36.94%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -36.94% vs -94.74% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-102.90
-59.80
-72.07%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-95.90
-54.70
-75.32%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -75.32% vs -43.57% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Savara, Inc. stock-summary
stock-summary
Savara, Inc.
Pharmaceuticals & Biotechnology
Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.
Company Coordinates stock-summary
Company Details
900 S Capital of Texas Hwy Ste 150 , WEST LAKE HILLS TX : 78746-5436
stock-summary
Tel: 1 512 6141848
stock-summary
http://savarapharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."